(NASDAQ: BLRX) Biolinerx's forecast annual revenue growth rate of 99.97% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Biolinerx's revenue in 2024 is $4,800,000.On average, 2 Wall Street analysts forecast BLRX's revenue for 2024 to be $15,608,853,355, with the lowest BLRX revenue forecast at $13,484,571,538, and the highest BLRX revenue forecast at $17,733,135,173.
In 2025, BLRX is forecast to generate $30,174,581,112 in revenue, with the lowest revenue forecast at $23,035,690,298 and the highest revenue forecast at $37,313,471,926.